Project description DEENESFRITPL Providing organ support to Covid-19 patients Nearly 60 % of patients in the intensive care unit (ICU) die of multiple organ failure. The ADVOS device has been shown to improve survival of critically ill patients by up to 30 % through blood purification and the removal of carbon dioxide, which reduces the need for ventilatory support. The EU-funded ADVOS-COVID-19 project aims to make the ADVOS system available to Covid-19 patients hospitalised in the ICU, expediting device production and installation in Germany and other EU countries. The idea is to support more ICU patients with ADVOS rather than standard haemodialysis devices and offer advanced liver, lung and kidney support. Show the project objective Hide the project objective Objective ADVITOS` innovation – the ADVOS therapy system - has the potential to increase the survival of COVID-19 patients suffering from severe multi organ failure (MOF). First published clinical data show that ADVOS improves survival by up to 30% in critically ill patients on intensive care. The first COVID-19 patient with MOF is being treated with ADVOS in Germany at present with promising results. ADVITOS is a SME instrument Phase 2 beneficiary: ADVOS 880349 for device usability improvement, IoT integration, and market expansion (2.3m€ grant). Following the urgent EU call for corona solutions, we apply now for the blended finance option to speed up device production and installation in Germany and other EU countries. The applied funding and equity is necessary in therapy application, service and sales resources as well as accelerated clinical evidence for medical indication guidance. Integrating fluid-based blood oxygenation for comprehensive lung support and AI/digital capabilities will achieve additional therapy and outcome improvement. Each year, 60% of intensive care patients - 500,000 individuals in Western Europe and the US - die of MOF. The coronavirus outbreak will further increase this number dramatically as COVID-19 often leads to MOF. The innovative ADVOS therapy has the potential to revolutionize intensive care therapy of patients worldwide, as it is the 1st and only blood purification therapy combining liver, lung, kidney support and direct blood pH correction in 1 device (technology leader in removal of liver toxins and fast extracorporeal blood pH correction). It will help to save lives in the current Corona crisis.The ADVOS therapy is low-invasive as standard hemodialysis, so it can support by far more ICU patients than other devices (that have a higher risk profile). This relates especially to the removal of CO2 (by ADVOS) which relieves the lung and reduces the need/invasiveness of ventilation. Fields of science medical and health scienceshealth sciencesinfectious diseasesRNA virusescoronaviruses Keywords SARS-CoV-2 Infection COVID-19 Corona virus multiple organ failure critical care hemodialysis technology extracorporeal treatment improvement of survival health economics Programme(s) H2020-EU.2.3. - INDUSTRIAL LEADERSHIP - Innovation In SMEs Main Programme H2020-EU.3. - PRIORITY 'Societal challenges H2020-EU.2.1. - INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies Topic(s) EIC-SMEInst-2018-2020 - SME instrument Call for proposal H2020-EIC-SMEInst-2018-2020 See other projects for this call Sub call H2020-EIC-SMEInst-2018-2020-3 Funding Scheme SME-2 - SME instrument phase 2 Coordinator ADVITOS GMBH Net EU contribution € 951 946,10 Address AGNES POCKELS BOGEN 1 80992 Munich Germany See on map SME The organization defined itself as SME (small and medium-sized enterprise) at the time the Grant Agreement was signed. Yes Region Bayern Oberbayern München, Kreisfreie Stadt Activity type Private for-profit entities (excluding Higher or Secondary Education Establishments) Links Contact the organisation Opens in new window Participation in EU R&I programmes Opens in new window HORIZON collaboration network Opens in new window Total cost € 1 381 605,00
